NervGen appoints Adam Rogers as permanent CEO

NervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN) announced that its board of directors has appointed Adam Rogers as president and chief executive officer, effective immediately. Rogers had been serving as interim CEO since July 2025.

The clinical-stage biopharmaceutical company develops neuroreparative therapeutics for spinal cord injury and other neurologic conditions. Rogers, a board-certified ophthalmologist, has served on NervGen's board since July 2022.

"Following a thorough evaluation during Adam's tenure as Interim CEO, the Board concluded that his leadership has been defined by results," said Craig Thompson, independent director and member of the nominating and corporate governance committee.

In connection with the appointment, NervGen granted Rogers 717,891 stock options. Of these, 614,799 options are exercisable at $5.06 per share for ten years, while 103,092 options are exercisable at $5.57 per share for five years. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting monthly over 36 months.

Rogers previously co-founded Hemera Biosciences, where he served as CEO from 2017 until December 2020, when Janssen Pharmaceuticals acquired rights to its lead program. He is currently a principal at Boston-based PFP Biosciences Holdings.

NervGen's lead therapeutic candidate, NVG-291, is a neuroreparative peptide for spinal cord injury treatment. The drug has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency. The company is conducting Phase 1b/2a clinical trials and preparing for a Phase 3 trial in chronic spinal cord injury.

You May Also Be Interested In

• RT Specialty names Brendan Mulshine as CEO in planned leadership change
• Passage Bio and Remix Therapeutics agree to all-stock merger deal
• Spruce Power director Ja-chin Audrey Lee resigns from board